Sanofi announced the launch of a new 12 Units dosage strength of Afrezza (insulin [human, recombinant]) inhalation powder. It was approved by the Food and Drug Administration (FDA) in June 2014 to improve glycemic control in adults with diabetes mellitus.
Afrezza, a rapid-acting inhaled insulin, lowers blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. It inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.
Afrezza is already available in 4 Units and 8 Units dosage strengths as single-dose, color-coded cartridges. Three cartridges are contained in a single blister strip. Each card contains 5 blister strips for a total of 15 cartridges.
For more information call (800) 633-1610 or visit Afrezza.com.